Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Nuvectis Pharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055318
| Line item | Three Months Ended March 31 / 2026 | Three Months Ended March 31 / 2025 |
|---|---|---|
| OPERATING EXPENSES | ||
| Research and development | $4,106 | $3,680 |
| General and administrative | 2,154 | 1,888 |
| OPERATING LOSS | (6,260) | (5,568) |
| Finance income | 210 | 236 |
| NET LOSS | $(6,050) | $(5,332) |
| TOTAL NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | $(6,050) | $(5,332) |
| BASIC AND DILUTED NET LOSS PER COMMON SHARE OUTSTANDING, see Note 6 | $(0.26) | $(0.27) |
Item 1. Financial Statements
FAQ
- What is Nuvectis Pharma, Inc.'s G&A?
- Nuvectis Pharma, Inc. (NVCT) reported G&A of $2.15M in Q1 2026.
- How has Nuvectis Pharma, Inc.'s G&A changed year-over-year?
- Nuvectis Pharma, Inc.'s G&A increased by 14.1% year-over-year, from $1.89M to $2.15M.
- What is the long-term trend for Nuvectis Pharma, Inc.'s G&A?
- Over 4 years (2021 to 2025), Nuvectis Pharma, Inc.'s G&A has grown at a 29.5% compound annual growth rate (CAGR), from $3.35M to $9.42M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Nuvectis Pharma, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude